{"denoms":[{"counts":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"11"},{"groupId":"BG008","value":"164"}],"units":"Participants"}],"groups":[{"description":"Patients receive 3mg/kg nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Initial Single"},{"description":"Patients receive 3mg/kg nivolumab IV over 30 minutes and 1mg/kg ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive 3mg/kg nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"BG001","title":"Initial Dual"},{"description":"Dedifferentiated liposarcoma (LPS) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"BG002","title":"LPS Single"},{"description":"Dedifferentiated liposarcoma (LPS) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes and 1mg/kg ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive 3mg/kg nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.","id":"BG003","title":"LPS Dual"},{"description":"Undifferentiated Pleomorphic Sarcoma \\& Malignant Fibrous Histiocytoma (UPS/MFH) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"BG004","title":"UPS/MFH Single"},{"description":"Undifferentiated Pleomorphic Sarcoma \\& Malignant Fibrous Histiocytoma (UPS/MFH) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes and 1mg/kg ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive 3mg/kg nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.","id":"BG005","title":"UPS/MFH Dual"},{"description":"Gastrointestinal stromal tumor (GIST) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"BG006","title":"GIST Single"},{"description":"Gastrointestinal stromal tumor (GIST) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes and 1mg/kg ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive 3mg/kg nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.","id":"BG007","title":"GIST Dual"},{"description":"Total of all reporting groups","id":"BG008","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"21.0","upperLimit":"76.0","value":"56.0"},{"groupId":"BG001","lowerLimit":"27.0","upperLimit":"81.0","value":"57.0"},{"groupId":"BG002","lowerLimit":"27.0","upperLimit":"82.0","value":"62.0"},{"groupId":"BG003","lowerLimit":"46.0","upperLimit":"68.0","value":"58.5"},{"groupId":"BG004","lowerLimit":"34.0","upperLimit":"85.0","value":"63.5"},{"groupId":"BG005","lowerLimit":"44.0","upperLimit":"84.0","value":"60.0"},{"groupId":"BG006","lowerLimit":"41.0","upperLimit":"79.0","value":"69.0"},{"groupId":"BG007","lowerLimit":"40.0","upperLimit":"81.0","value":"62.0"},{"groupId":"BG008","lowerLimit":"27","upperLimit":"85","value":"62"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"77"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"6"},{"groupId":"BG008","value":"87"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"2"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"12"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"7"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"142"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"5"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"90"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"74"}],"title":"1"}]}],"description":"Eastern Cooperative Oncology Group PS Scale: 0)Fully active, able to carry on all pre-disease performance without restriction; 1)Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2)Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3)Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4)Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"Randomized patients are included in this analysis."}